Anirban Maitra: Arjun Gupta’s Patients’ considerations of time toxicity
ASCO PallOnc Community of Practice shared Anirban Maitra’s post on X, adding:
“Emphasizes the need to discuss treatment-related time toxicity along with potential survival benefits (if any), enabling patients to make informed decisions about their care.”
Quoting Anirban Maitra’s post on X, about a recent paper by Arjun Gupta et al. titled “Patients considerations of time toxicity when assessing cancer treatments with marginal benefit” published in Oxford Academic.
Authors: Arjun Gupta, Michael Brundage, Jacqueline Galica, Safiya Karim, Rachel Koven, Terry Ng, Jennifer O’Donnell, Julia TenHove, Andrew Robinson, Christopher Booth
“No rocket science, just good old common sense oncology. From one of the leading experts in ‘time toxicity’ of cancer therapies, Arjun Gupta’s patients‘ considerations of time toxicity when assessing cancer treatments with marginal benefit”
Source: Anirban Maitra/X
Dr. Anriban Maitra serves as Professor of Pathology and Translational Molecular Pathology at UT MD Anderson Cancer Center since August 2013, and directs the Sheikh Ahmed Pancreatic Cancer Research Center.
He leads an NCI-funded laboratory dedicated to pancreatic cancer research, focusing on genetics and molecular pathology in human and mouse models. His research aims to advance early detection and interception strategies to enhance patient survival rates in pancreatic cancer.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023